4.2 Article

Human Rhinovirus Infections in Hematopoietic Cell Transplant Recipients: Risk Score for Progression to Lower Respiratory Tract Infection

Journal

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 25, Issue 5, Pages 1011-1021

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2018.12.005

Keywords

Rhinovirus; Viral pneumonia; Hematopoietic cell transplantation; Respiratory virus

Funding

  1. National Institutes of Health (National Institute of Allergy and Infectious Diseases) [K23 AI114844]
  2. National Institutes of Health (National Heart, Lung, and Blood Institute) [K24 HL093294]
  3. National Institutes of Health (National Cancer Institute) [P30 CA15704]
  4. Vaxart, Inc.

Ask authors/readers for more resources

Human rhinovirus lower respiratory tract infection (LRTI) is associated with mortality after hematopoietic cell transplantation (HCT); however, risk factors for LRTI are not well characterized. We sought to develop a risk score for progression to LRTI from upper respiratory tract infection (URTI) in HCT recipients. Risk factors for LRTI within 90 days were analyzed using Cox regression among HCT recipients with rhinovirus URTI between January 2009 and March 2016. The final multivariable model included factors with a meaningful effect on the bootstrapped optimism corrected concordance statistic. Weighted score contributions based on hazard ratios were determined. Cumulative incidence curves estimated the probability of LRTI at various score cut-offs. Of 588 rhinovirus URTI events, 100 (17%) progressed to LRTI. In a final multivariable model allogeneic grafts, prior rhinovirus URTI, low lymphocyte count, low albumin, positive cytomegalovirus serostatus, recipient statin use, and steroid use >= 2 mg/kg/day were associated with progression to LRTI. A weighted risk score cut-off with the highest sensitivity and specificity was determined. Risk scores above this cut-off were associated with progression to LRTI (cumulative incidence 28% versus 11% below cut-off; P < .001). The weighted risk score for progression to rhinovirus LRTI can help identify and stratify patients for clinical management and for future clinical trials of therapeutics in HCT recipients. (C) 2018 American Society for Blood and Marrow Transplantation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available